Comparing clinical outcomes between two continuous glucose monitors: similar diabetes-related events, all-cause hospitalizations and HbA1c reductions in type 1 and type 2 diabetes
American Journal of Medicine Open · 2023
DOI: 10.1016/j.ajmo.2022.100008 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medicine Open, 2023. Verfasst von Eden Miller und 7 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Obesity Care, Bend, OR, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Abbott Laboratories, Abbott Diabetes Care Inc.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objectives
We compared clinical outcomes after acquiring a FreeStyle Libre© Flash Continuous Glucose Monitoring System (FSL) or Dexcom (DEX) continuous glucose monitoring (CGM) device in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) treated with intensive insulin therapy. Design and Methods: This retrospective analysis of the IBM® MarketScan® Research Databases and IBM® Explorys® Electronic Health Records Database assessed differences in acute diabetes-related events (ADE), all-cause hospitalizations (ACH) and glycated hemoglobin (HbA1c) in T1D and T2D populations 6 months post CGM acquisition. Analyses were conducted in two study cohorts (Cohort 1, n = 7,494; Cohort 2, n = 678). Participants were T1D or T2D, age ≥ 18 years, treated with short or rapid-acting insulin and naïve to CGM, who acquired a CGM system. Users were propensity score matched on demographics and clinical factors.
Results
Cohort 1: Post-CGM ADE-free rates at 6 months ranged from 94.8 to 96.7% and ACH-free rates ranged from 90.4 to 95.4%, for both T1D and T2D groups, with no significant differences between CGM systems. Cohort 2: Significant HbA1c reductions were associated with use of the DEX and FSL devices in the T1D (-0.35% and -0.37%, respectively) and T2D (-0.73% and -0.79%, respectively) cohorts, both p < 0.001, with no significant differences in the magnitude of reduction between systems (T1D p = 0.99 and T2D p = 0.84).
Conclusions
Acquisition of the FSL and DEX systems was associated with similar rates of acute diabetes-related events and all-cause hospitalizations and similar HbA1c reductions in adults with T1D and T2D.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Diabetes and Obesity Care, Bend, OR, USA.
- Abbott, Sylmar, CA, USA.
- Abbott, Santa Clara, CA, USA.
- Abbott Diabetes Care, Alameda, CA, USA.
- University of Washington School of Medicine, Seattle, WA, USA.
Förderung
- Abbott Laboratories
- Abbott Diabetes Care Inc
Zitieren
APA
Miller, E., Roberts, G. J., Joseph, J. M., Nabutovsky, Y., Reyes, I. J., Souto, D., Virdi, N., & Hirsch, I. B. (2023). Comparing clinical outcomes between two continuous glucose monitors: similar diabetes-related events, all-cause hospitalizations and HbA1c reductions in type 1 and type 2 diabetes. American Journal of Medicine Open. https://doi.org/10.1016/j.ajmo.2022.100008
Vancouver
Miller E, Roberts GJ, Joseph JM, Nabutovsky Y, Reyes IJ, Souto D, et al. Comparing clinical outcomes between two continuous glucose monitors: similar diabetes-related events, all-cause hospitalizations and HbA1c reductions in type 1 and type 2 diabetes. American Journal of Medicine Open. 2023. doi:10.1016/j.ajmo.2022.100008
BibTeX
@article{Miller2023,
author = {Miller, Eden and Roberts, Gregory J and Joseph, Jennifer M and Nabutovsky, Yelena and Reyes, Ignacio J and Souto, Diana and Virdi, Naunihal and Hirsch, Irl B},
title = {Comparing clinical outcomes between two continuous glucose monitors: similar diabetes-related events, all-cause hospitalizations and HbA1c reductions in type 1 and type 2 diabetes},
journal = {American Journal of Medicine Open},
year = {2023},
doi = {10.1016/j.ajmo.2022.100008}
}
EUVIMED